Regular sessions can help maintain focus, endurance, and immune strength throughout the year
Simultaneous start protocol (standard approach) When to use: Starting both peptides fresh (no prior use) Following clinical trial model exactly Want maximum proven efficacy Can tolerate both from beginning Week-by-week dosing schedule: Weeks 1-4: Semaglutide: 0.25mg weekly Cagrilintide: 0.6mg weekly Inject same day OR different days (preference) Separate injection sites if same day Tips: Start ginger supplementation, small meals, hydrate well Weeks 5-8: Semaglutide: 0.5mg weekly (2x increase) Cagrilintide: 1.2mg weekly (2x increase) Nausea typically increases this phase Tips: Anti-nausea meds ready, protein shakes if needed, slow eating Weeks 9-12: Semaglutide: 1.0mg weekly Cagrilintide: 1.8mg weekly Peak side effect window Tips: May need to extend by 1-2 weeks if struggling, Zofran helpful Weeks 13-16: Semaglutide: 1.7mg weekly Cagrilintide: 2.4mg weekly (cagrilintide at target) Semaglutide still escalating Tips: Cagrilintide side effects should be stabilizing Week 17+: Semaglutide: 2.4mg weekly (both at maximum) Cagrilintide: 2.4mg weekly Maintenance dosing Continue indefinitely Tips: Side effects typically moderate by now (adapted) Injection logistics: Both subcutaneous injections Can inject same day (different sites: left/right abdomen) OR split: Semaglutide Monday, Cagrilintide Thursday Rotate sites to prevent irritation 29-31 gauge insulin syringes See our peptide injections guide , how to reconstitute peptides , and peptide dosing guide
Pregnancy planning: Semaglutide has a long half-life and is generally stopped well before conception
J Clin Endocrinol Metab 95:24862491 [DOI] [PMC free article] [PubMed] [Google Scholar] Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, Furlanetto R, Rogol AD, Kaiser DL, Thorner MO 1987 Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations
Research published in obesity journals shows that people who stop GLP-1 therapy regain an average of 50% of lost weight within 6 months without additional intervention
The serum malondialdehyde levels in the N-acetylcysteine group were significantly decreased compared to the socially isolated stress group receiving normal saline (Fig
